Culturally and linguistically diverse patient participation in glioma research

摘要: Marginal communities, such as culturally and linguistically diverse (CALD) patients, have significantly lower rates of recruitment, accrual, retention in cancer clinical trials. A combination language cultural barriers means that trial participation from CALD communities remains at suboptimal levels, which turn favors research findings are biased towards therapeutic effects or toxicities within the context non-CALD populations. Here we outline some key challenges implications for patient glioma countries Australia, where English is governance health services implementation. We highlight multistakeholder interventions to improve both investigator recruitment future research, particularly this era when global migration has come age. Enhancing ensures not only wider understanding genetic heterogeneity outcomes but also equity access care.